Search
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)
smpdb.ca/view/SMP0125791DiseaseThis disorder is characterized by a large accumulation of lactic acid in the blood. … Symptoms of the disorder include hepatomegaly, failure to thrive and liver failure, depending on the severity of the case. Treatment including heavy carbohydrates and fasting is very effective.
Fructose-1,6-diphosphatase Deficiency
smpdb.ca/view/SMP0125792DiseaseFBP1D is characterized by hypoglycemia and acidosis after fasting, caused by the impairment of gluconeogenesis. Symptoms can also include hyperventilation. … It is estimated that FBP1D affects between 1 in 350,000 and 1 in 900,000 individuals.
Mesoridazine Dopamine Antagonist Action Pathway
smpdb.ca/view/SMP0126523Drug actionMesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer and a first generation typical antipsychotic.
Enzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptorPhenprocoumon Action Pathway
smpdb.ca/view/SMP0000271Drug actionAs vitamin K is a cofactor for the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulation factors (II, VII, IX, and X), this ultimately results in reduced cleavage of fibrinogen … into fibrin and decreased coagulability of the blood.
Enzymes: Vitamin K-dependent gamma-carboxylase, Vitamin K epoxide reductase complex subunit 1Modafinil Action Pathway
smpdb.ca/view/SMP0125075Drug actionOther commonly reported adverse effects (5% to 10% of users) include anxiety, insomnia, dizziness, diarrhea, and rhinitis … The most commonly reported adverse effects of modafinil (less than 10% of users) are a headache, nausea, and decreased appetite.
Enzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptorSulpiride Mechanism of Action Action Pathway
smpdb.ca/view/SMP0126479Drug actionSulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist indicated to treat acute and chronic schizophrenia. … Sulpiride is a selective dopamine D2 and D3 receptor antagonist.
Enzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptorLoxapine Dopamine Antagonist Action Pathway
smpdb.ca/view/SMP0126481Drug actionLoxapine is a dopamine antagonist and serotonin 5-HT2 blocker.
Enzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptorProchlorperazine - Dopamine Antagonist Action Pathway
smpdb.ca/view/SMP0126629Drug actionIt is a phenothiazine derivative, used in the treatment of schizophrenia and anxiety and to relieve severe nausea and vomiting. … It depresses the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.
Drugs: Pyridoxal phosphate · Tyrosine · Sapropterin · Prochlorperazine · Dopamine · Levodopa +2 moreEnzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptorWarfarin Action Pathway (New)
smpdb.ca/view/SMP0124982Drug actionBy doing this the carboxylation of vitamin-k dependent factors such as II, VII, IX and X are prevented. … Warfarin is a [vitamin K] antagonist which acts to inhibit the production of vitamin K by inhibiting vitamin K epoxide reductase.
Enzymes: Vitamin K-dependent gamma-carboxylase, Vitamin K epoxide reductase complex subunit 1Quetiapine Dopamine Antagonist Action Pathway
smpdb.ca/view/SMP0126827Drug actionAdditional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 … In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors.
Enzymes: Aromatic-L-amino-acid decarboxylase, D(2) dopamine receptor